Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 192

Sort by

Sort Order Select

Journal Articles

Patient Satisfaction with Quality of Care of a New Multidisciplinary Thrombosis Service

Stephanie W Young, PharmD, Kwadwo Osei Bonsu, BPharm(Hons), PhD, Tiffany Lee, BSc(Pharm), Pharm.D, Hai V Nguyen, PhD, Rufaro S Chitsike, MBChB, MMed(Haem), FCPath(Haem), Cert Clin(Haem)

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-138855

Published: 2020

Journal Articles

Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel

Paolo Strati, MD, Grace Watson, Sandra B. Horowitz, Pharm.D., Ranjit Nair, MD, Maria Alma Rodriguez, MD, Raphael Eric Steiner, MD, Luis Fayad, Jason R. Westin, MD, Sattva S. Neelapu, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-135835

Published: 2020

Journal Articles

Unusual Case of Hepatic Sinusoidal Obstruction Syndrome Induced By Low Dose Oral Cyclophosphamide

Pramod Gaudel, MD, Jordan Snyder, Pharm.D, Abdulraheem Yacoub, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-141516

Published: 2020

Journal Articles

A Single Center Review Evaluating Daratumumab Outcomes in Multiple Myeloma Patients at Monter Cancer Center/Northwell Health Cancer Institute

Chung H Chen, Chung-Shien Lee, Pharm.D, Samrah Ahmad, PharmD, BCPS, CACP, BCOP, Monique Hartley-Brown, MD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-143203

Published: 2020

Journal Articles

Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, MD, Gail J. Roboz, MD, Marina Konopleva, MD PhD, Hongtao Liu, MD PhD, Elias Jabbour, MD, Camille Poirot, Pharm.D., Cécile Schiffer-Manniou, PhD, Agnès Gouble, PhD, Asifa Haider, PhD, Oleg Zernovak, MD, Richard A. Larson, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138594

Published: 2020

Journal Articles

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Ahmad H. Mattour, MD, Leslie L. Popplewell, MD FACP, Charalambos Andreadis, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Jonah Shulman, MD, Sudhir Manda, MD, John M. Burke, MD, Saurabh Chhabra, MD, Jeff P Sharman, MD, Amrita Krishnan, MD, Nina Shah, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, MBA, Craig Jerome Berman, MD, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139829

Published: 2020

Journal Articles

Phase 1 Trial of Prophylactic Donor-Derived IL-2 Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

Raynier Devillier, Boris Calmels, Pharm.D., Sophie Guia, Cyril Fauriat, Sabine Furst, Samia Harbi, Angela Granata, MD, Sophie Ugolini, Christian Chabannon, MD PhD, Daniel Olive, MD PhD, Eric Vivier, Didier Blaise, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140753

Published: 2020

Journal Articles

Hyperfractionated Cyclophosphamide-Dexamethasone (HyperCy-Dex) with or without Carfilzomib (Car) in Patients (pts) with Multiple Myeloma (MM)

Erin K. Yeung, Pharm.D., Brian R. Primeaux, Pharm.D., Sandra B. Horowitz, Pharm.D., Brandon R. Shank, Irene Y. Lee, Gregory P. Kaufman, MD, Hans C. Lee, MD, Elisabet E. Manasanch, MD, Krina K. Patel, MD, Robert Z. Orlowski, MDPhD, Donna M. Weber, MD, Sheeba K. Thomas, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-137704

Published: 2020

Journal Articles

Safety and Tolerability of Intra-Venous Ascorbic Acid in Allogeneic Hematopoietic Cell Transplant Recipients: A Matched Historical Control Study

Gary Simmons, DO, Roy Sabo, PhD, Maja Radic, BS, May Aziz, Pharm.D, Kelly Hawks, Pharm.D, Robyn J Bernard, BS, Ali Jafri, BS, Catherine H Roberts, PhD, Ramesh Natarajan, Alpha Fowler, Amir Ahmed Toor, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-138543

Published: 2020

Journal Articles

A Systematic Literature Review of the Burden of Central Nervous System Complications for Patients with Sickle Cell Disease

Soyon Lee, Pharm.D., Dave Nellesen, PhD, Sedge Lucas, B.A., Jincy Paulose, MD, Vivien A. Sheehan, MDPhD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-140533

Published: 2020

Journal Articles

Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Melody R Becnel, MD, Sandra B. Horowitz, Pharm.D., Sheeba K. Thomas, MD, Swami P. Iyer, MD, Krina K. Patel, MD, Elisabet E. Manasanch, MD, Donna M. Weber, MD, Gregory P. Kaufman, MD, Hans C. Lee, MD, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140526

Published: 2020

Journal Articles

Successful Clearance of Donor Specific Anti-HLA Antibodies after Desensitization with Rituximab, Velcade and Plasma-Exchange Followed By a Haploidentical Stem Cell Transplantion with Post-Transplantation Cyclophosphamide

Sabine Furst, Valerio Maisano, MD, Agnes Basire, Angela Granata, MD, Faezeh Legrand, MD, Raynier Devillier, Samia Harbi, Luca Castagna, MD, Christophe Picard, Claude Lemarie, Pharm.D., Christian Chabannon, MD PhD, Didier Blaise, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142473

Published: 2020

Journal Articles

Patient Adherence to Medication within a New Multidisciplinary Thrombosis Service

Kwadwo Osei Bonsu, BPharm(Hons), PhD, Stephanie W Young, PharmD, Tiffany Lee, BSc(Pharm), Pharm.D, Hai V Nguyen, PhD, Rufaro S Chitsike, MBChB, MMed(Haem), FCPath(Haem), Cert Clin(Haem)

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-140704

Published: 2020

Journal Articles

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Margaux Damge, Sabine Furst, MD, Bénédicte Devictor, Samia Harbi, MD, Joseph Ciccolini, Angela Granata, MD, Thomas Pagliardini, MD, Boris Calmels, Pharm.D., Claude Lemarie, Pharm.D., Luca Castagna, MD, Valerio Maisano, MD, Faezeh Legrand, MD, Anne-Marie Stoppa, MD, Reda Bouabdallah, Evelyne D'Incan, Norbert Vey, MD PhD, Christian Chabannon, MD PhD, Didier Blaise, MD PhD, Raynier Devillier, MD PhD

Blood (2019) 134 (Supplement_1): 4503.

https://doi.org/10.1182/blood-2019-125994

Published: 2019

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Blood (2019) 134 (Supplement_1): 5474.

https://doi.org/10.1182/blood-2019-126698

Published: 2019

Journal Articles

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Blood (2019) 134 (Supplement_1): 4106.

https://doi.org/10.1182/blood-2019-127094

Published: 2019

Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA

Blood (2019) 134 (Supplement_1): 1845.

https://doi.org/10.1182/blood-2019-126606

Published: 2019

Journal Articles

Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using Plerixafor

Alexis Leonard, MD, Naoya Uchida, MD, David F. Stroncek, MD, Sandhya R. Panch, MDMPH, Kamille West, Eoghan George Molloy, MD, Tom Hughes, Pharm.D., Sara Hauffe, RN, Tiffani Taylor, Courtney D. Fitzhugh, MD, Jane S. Hankins, MD MS, Megan Wilson, MSW, CCRP, Akshay Sharma, MBBS, Shengdar Q. Tsai, PhD, Mitchell J. Weiss, MD, PhD, Matthew Hsieh, MD, John F. Tisdale, MD

Blood (2019) 134 (Supplement_1): 1964.

https://doi.org/10.1182/blood-2019-126091

Published: 2019

Journal Articles

Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing Phase I/II Clinical Study

Blood (2019) 134 (Supplement_1): 2058.

https://doi.org/10.1182/blood-2019-126746

Published: 2019

NARROW

Patient Satisfaction with Quality of Care of a New Multidisciplinary Thrombosis Service

Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel

Unusual Case of Hepatic Sinusoidal Obstruction Syndrome Induced By Low Dose Oral Cyclophosphamide

A Single Center Review Evaluating Daratumumab Outcomes in Multiple Myeloma Patients at Monter Cancer Center/Northwell Health Cancer Institute

Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Phase 1 Trial of Prophylactic Donor-Derived IL-2 Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

Hyperfractionated Cyclophosphamide-Dexamethasone (HyperCy-Dex) with or without Carfilzomib (Car) in Patients (pts) with Multiple Myeloma (MM)

Safety and Tolerability of Intra-Venous Ascorbic Acid in Allogeneic Hematopoietic Cell Transplant Recipients: A Matched Historical Control Study

A Systematic Literature Review of the Burden of Central Nervous System Complications for Patients with Sickle Cell Disease

Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Successful Clearance of Donor Specific Anti-HLA Antibodies after Desensitization with Rituximab, Velcade and Plasma-Exchange Followed By a Haploidentical Stem Cell Transplantion with Post-Transplantation Cyclophosphamide

Patient Adherence to Medication within a New Multidisciplinary Thrombosis Service

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using Plerixafor

Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing Phase I/II Clinical Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only